Complex Regional Pain Syndrome emerges following injury, surgery, or sometimes without clear precipitant, characterised by disproportionate pain, autonomic dysfunction, motor impairment, and inflammatory skin changes confined to a limb. Current management relies on physiotherapy, pain medications, and neuromodulation, yet many patients experience chronic refractory symptoms and functional disability. Stem cell research into CRPS explores whether placental mesenchymal stem cells or neurogenic derivatives might dampen persistent inflammatory signalling and promote peripheral nerve plasticity. These approaches remain at an early clinical stage, with no established cell therapy standard of care.
Two registered clinical trials are actively investigating stem cell interventions in CRPS populations. One multicentre trial examined intravenous allogeneic placental MSCs in 34 CRPS patients; preliminary results reported pain reduction (measured on 0–100 numerical rating scale) averaging 28–32 points at 12 weeks, compared to 8–12 points in sham controls. A second smaller trial of neurogenic precursor cells showed subjective functional improvement in hand dexterity tasks. Neither trial has reported long-term follow-up beyond 6 months. No major efficacy data have been published in peer-reviewed journals. Mechanistic research continues.
Stem cell treatments for CRPS delivered at European and Asian clinics typically cost €4,500–€9,000 per infusion. Private UK practitioners may charge £6,000–£10,000 for consultations plus administration. Insurance coverage is exceptionally rare, as therapies lack regulatory approval and CRPS guidelines do not recommend cellular interventions. Self-funding is standard. International travel, accommodation, and follow-up care add substantially to out-of-pocket expense. Comparison to conventional CRPS management (physiotherapy ~£50–100 per session, medications <£100 monthly) reveals a significant financial threshold.
Cell therapy for Complex Regional Pain Syndrome is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Complex Regional Pain Syndrome programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Complex Regional Pain Syndrome overview · Complex Regional Pain Syndrome cost →
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite